Glympse Bio

#NEWS: Glympse Bio is now merged with Sunbird Bio! Read the press release: sunbirdbio.com/news/Sunbird-B…

Speaking with @karenjagoda of the Empowered Patient Podcast, CMO Dr. Tram Tran discusses how Glympse’s #diagnostic platform simplifies things in the clinic and for the patient using a simple blood-based test. Listen to the podcast here: empoweredpatientradio.com/disease-activi…

On behalf of the entire team at Glympse, we hope you have a very happy Thanksgiving!

Glympse is developing #technology that can non-invasively measure protein activity to #diagnose and monitor disease. Learn more by viewing the animation on our website: glympsebio.com/technology/

Watch: Dr. Amit Singal (@docamitgs) of @utswcancer discusses the need for early #HCC diagnosis and the #TLM22 data demonstrating that Glympse's biosensor platform can sensitively detect HCC. glympsebio.com/video-aasld-tl…

#TLM22 begins today! Glympse and Dr. Amit Singal (@docamitgs) will present a poster on Monday 11/7 from 1-2 PM that demonstrates our biosensors can sensitively detect HCC. We hope to see you then! You can view the poster on our website: glympsebio.com/news/?tx_categ… @AASLDtweets

Glympse will present a poster at @AASLDtweets #TLM22 demonstrating the sensitive detection of #HCC by our novel diagnostic platform. You can see the poster on Monday, Nov. 7 from 1-2 PM and find more information in our announcement: prnewswire.com/news-releases/…

A recent @HealioGastro article highlights how #NASH is the fastest growing cause of hepatocellular carcinoma (#HCC) in the US and of #livercancer deaths worldwide. Glympse’s platform and diagnostic potential seeks to help reverse this trend. healio.com/news/gastroent…

Glympse celebrated the #autumn season with an #applepicking event! We had a wonderful day spending this quality time together as a team. #teamwork

October is #LiverAwarenessMonth. Liver disease takes many forms and can significantly impact a patient's quality of life. Glympse is dedicated to developing diagnostics to help improve treatments for patients with #liverdisease. Learn more from @liverUSA: bit.ly/3fMTcXj

#ICYMI, our #CMO Tram Tran, MD, wrote an article for @Tech_Networks about the burden of #liverdisease on the healthcare system and the role #diagnostics like Glympse’s can play in alleviating this. Read Tram’s article here: technologynetworks.com/diagnostics/bl…

Shout out to our new #CSO, Dr. Jonathan Wilde! Since joining the team earlier this year, Dr. Wilde’s scientific expertise has been integral in the development of our novel protein activity biosensor #diagnostic platform.

On this week’s episode of @PharmaVoice’s #WomanOfTheWeek podcast, CMO Dr. Tram Tran shares the inspirations that led to her career path in #medicine and work on Glympse’s revolutionary diagnostic technology. Listen to the full episode here: pharmavoice.com/news/woman-of-…

CMO Dr. Tram Tran sat down with @MyDocWire to discuss Glympse’s focus on early disease detection for #NASH and improving patient outcomes with its unique protein activity-based diagnostic platform. Watch: youtu.be/CxURIxVFa1E

#TeamGlympse wishes you a safe and happy #IndependenceDay!

Tomorrow, June 24, Dr. Amit Singal (@docamitgs) will present findings at #ILC2022 demonstrating that #Glympse’s biosensor platform can detect #HCC from non-HCC patients with liver cirrhosis from a blood sample. See the poster here: glympsebio.com/wp-content/upl…

On Saturday, June 25, CMO Tram Tran, M.D. will present a poster at @EASLNews’s #ILC2022 demonstrating our novel protease biosensor diagnostic platform’s ability to distinguish NASH vs. healthy patients from a blood sample. See the poster here: glympsebio.com/wp-content/upl…

#Glympse CMO @TramTran_MD spoke with @AnnetteMBoyle of @BioWorld about our @EASLnews #ILC2022 data demonstrating early detection of #HCC from a simple blood test and the importance of this for patients. Read more: bioworld.com/articles/51965…

Today is International #NASHDay. NASH is a severe form of fatty #liverdisease that affects millions worldwide. At #Glympse, we are developing technologies to improve how we diagnose and monitor NASH, so we can #StopNASHNow. Learn more from @globalliver: international-nash-day.com

#Glympse will present two posters on the accuracy of its protease biosensor diagnostic platform in detecting patients with hepatocellular carcinoma (#HCC) at the @EASLnews International Liver Congress 2022 #ILC2022. Find out more: prnewswire.com/news-releases/…